Elevated sEH levels have been observed in multiple neurological disorders including depression, Parkinson’s disease and AD and blocking of sEH activity has been shown to provide therapeutic benefit in related disease models [14, 16, 23, 25, 46–48]. This evidence concerns the gene EPHX2 and nervous system disorder.